Galapagos NV (GLPG.AS)
EUR 23.54
(-2.08%)
EUR 23.54
(-2.08%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 327.98 Million EUR | -50.67% |
| 2022 | 760.72 Million EUR | 17.25% |
| 2021 | 648.81 Million EUR | -1.2% |
| 2020 | 656.68 Million EUR | 38.34% |
| 2019 | 474.69 Million EUR | 42.27% |
| 2018 | 333.64 Million EUR | 53.83% |
| 2017 | 216.89 Million EUR | 53.81% |
| 2016 | 141.01 Million EUR | 9.3% |
| 2015 | 129 Million EUR | 22.49% |
| 2014 | 105.32 Million EUR | -0.99% |
| 2013 | 106.37 Million EUR | 17.95% |
| 2012 | 90.18 Million EUR | 2251.07% |
| 2011 | 3.83 Million EUR | -22.05% |
| 2010 | 4.92 Million EUR | -18.77% |
| 2009 | 6.05 Million EUR | -90.12% |
| 2008 | 61.3 Million EUR | 20.23% |
| 2007 | 50.98 Million EUR | 90.21% |
| 2006 | 26.8 Million EUR | 109.74% |
| 2005 | 12.78 Million EUR | 26.57% |
| 2004 | 10.09 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 114.13 Million EUR | 6.92% |
| 2024 Q2 | 106.74 Million EUR | 4.24% |
| 2024 Q1 | 102.4 Million EUR | 181.09% |
| 2023 Q2 | 156.37 Million EUR | 1.99% |
| 2023 FY | 375.3 Million EUR | -50.67% |
| 2023 Q1 | 153.32 Million EUR | -31.38% |
| 2023 Q4 | -126.27 Million EUR | -187.35% |
| 2023 Q3 | 144.56 Million EUR | -7.55% |
| 2022 Q3 | 171.39 Million EUR | -18.89% |
| 2022 Q1 | 154.58 Million EUR | -0.83% |
| 2022 Q2 | 211.31 Million EUR | 36.7% |
| 2022 Q4 | 223.44 Million EUR | 30.37% |
| 2022 FY | 760.72 Million EUR | 17.25% |
| 2021 Q4 | 155.87 Million EUR | 9.87% |
| 2021 FY | 648.81 Million EUR | -1.2% |
| 2021 Q1 | 164.69 Million EUR | 2.97% |
| 2021 Q2 | 186.52 Million EUR | 13.26% |
| 2021 Q3 | 141.86 Million EUR | -23.94% |
| 2020 Q4 | 159.94 Million EUR | -2.58% |
| 2020 FY | 656.68 Million EUR | 38.34% |
| 2020 Q3 | 164.17 Million EUR | -13.51% |
| 2020 Q2 | 189.81 Million EUR | 32.96% |
| 2020 Q1 | 142.75 Million EUR | 0.54% |
| 2019 Q2 | 103.1 Million EUR | 19.49% |
| 2019 FY | 474.69 Million EUR | 42.27% |
| 2019 Q4 | 141.99 Million EUR | -0.91% |
| 2019 Q1 | 86.29 Million EUR | -11.65% |
| 2019 Q3 | 143.3 Million EUR | 38.99% |
| 2018 FY | 333.64 Million EUR | 53.83% |
| 2018 Q2 | 83.42 Million EUR | 19.28% |
| 2018 Q3 | 82.6 Million EUR | -0.99% |
| 2018 Q1 | 69.94 Million EUR | 5.23% |
| 2018 Q4 | 97.67 Million EUR | 18.24% |
| 2017 Q3 | 56.59 Million EUR | 16.43% |
| 2017 FY | 216.89 Million EUR | 53.81% |
| 2017 Q2 | 48.6 Million EUR | 7.5% |
| 2017 Q1 | 45.21 Million EUR | 6.35% |
| 2017 Q4 | 66.46 Million EUR | 17.44% |
| 2016 Q4 | 42.52 Million EUR | 20.3% |
| 2016 Q2 | 35.62 Million EUR | 29.48% |
| 2016 FY | 141.01 Million EUR | 9.3% |
| 2016 Q1 | 27.51 Million EUR | -17.57% |
| 2016 Q3 | 35.34 Million EUR | -0.8% |
| 2015 Q4 | 33.38 Million EUR | 0.01% |
| 2015 Q1 | 30.12 Million EUR | -2.38% |
| 2015 FY | 129 Million EUR | 22.49% |
| 2015 Q3 | 33.37 Million EUR | 3.91% |
| 2015 Q2 | 32.12 Million EUR | 6.61% |
| 2014 Q1 | 3.99 Million EUR | -59.23% |
| 2014 FY | 105.32 Million EUR | -0.99% |
| 2014 Q4 | 30.86 Million EUR | 27.69% |
| 2014 Q3 | 24.17 Million EUR | 504.93% |
| 2014 Q2 | 3.99 Million EUR | 0.0% |
| 2013 Q3 | 9.8 Million EUR | -8.18% |
| 2013 Q4 | 9.8 Million EUR | 0.0% |
| 2013 Q2 | 10.67 Million EUR | 0.0% |
| 2013 Q1 | 10.67 Million EUR | -17.53% |
| 2013 FY | 106.37 Million EUR | 17.95% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | 12.94 Million EUR | 80.82% |
| 2012 FY | 90.18 Million EUR | 2251.07% |
| 2012 Q3 | 7.15 Million EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 FY | 3.83 Million EUR | -22.05% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 FY | 4.92 Million EUR | -18.77% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | 6.05 Million EUR | -90.12% |
| 2008 FY | 61.3 Million EUR | 20.23% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | 50.98 Million EUR | 90.21% |
| 2006 FY | 26.8 Million EUR | 109.74% |
| 2005 FY | 12.78 Million EUR | 26.57% |
| 2004 FY | 10.09 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -7752.216% |
| ABIVAX Société Anonyme | 127.37 Million EUR | -157.495% |
| Adocia SA | 15.62 Million EUR | -1998.58% |
| Aelis Farma SA | 18.81 Million EUR | -1642.85% |
| Biophytis S.A. | 14.33 Million EUR | -2188.335% |
| Advicenne S.A. | 8.21 Million EUR | -3892.538% |
| genOway Société anonyme | 16.73 Million EUR | -1859.502% |
| IntegraGen SA | 5.35 Million EUR | -6027.723% |
| Medesis Pharma S.A. | 1.56 Million EUR | -20863.369% |
| Neovacs S.A. | 10.34 Million EUR | -3070.934% |
| NFL Biosciences SA | 4.37 Million EUR | -7397.955% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -11762.741% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -18991.6% |
| Sensorion SA | 27.05 Million EUR | -1112.356% |
| Theranexus Société Anonyme | 3 Million EUR | -10814.756% |
| TME Pharma N.V. | 5.49 Million EUR | -5866.655% |
| Valbiotis SA | 9.86 Million EUR | -3223.407% |
| TheraVet SA | 1.64 Million EUR | -19846.75% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | -1514.109% |
| argenx SE | 1.34 Billion EUR | 75.572% |
| BioSenic S.A. | 7.58 Million EUR | -4225.293% |
| Celyad Oncology SA | 8.49 Million EUR | -3763.216% |
| DBV Technologies S.A. | 89.4 Million EUR | -266.852% |
| Genfit S.A. | 54.8 Million EUR | -498.473% |
| GeNeuro SA | 14.35 Million EUR | -2184.462% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | -1723.467% |
| Innate Pharma S.A. | 64.57 Million EUR | -407.956% |
| Inventiva S.A. | 120.18 Million EUR | -172.9% |
| MaaT Pharma SA | 21.59 Million EUR | -1418.599% |
| MedinCell S.A. | 32.92 Million EUR | -896.255% |
| Nanobiotix S.A. | 58.92 Million EUR | -456.599% |
| Onward Medical N.V. | 20.64 Million EUR | -1488.699% |
| Oryzon Genomics S.A. | 18.49 Million EUR | -1673.18% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | -1290.424% |
| Oxurion NV | 12.21 Million EUR | -2585.336% |
| Pharming Group N.V. | 204.24 Million EUR | -60.581% |
| Poxel S.A. | 28.76 Million EUR | -1040.229% |
| GenSight Biologics S.A. | 32.66 Million EUR | -904.247% |
| Transgene SA | 31.23 Million EUR | -950.197% |
| Financière de Tubize SA | 114.38 Thousand EUR | -286629.493% |
| UCB SA | 2.94 Billion EUR | 88.848% |
| Valneva SE | 134.92 Million EUR | -143.09% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | -1228.313% |